Opdivo, Bristol-Myers Squibb and Non-Small Cell Lung Cancer

FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors,
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why I'm bullish on BMY heading into 2025.
(Nivolumab + relatlimab) by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.
US FDA approves injectable form of Bristol Myers' Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. (Reporting by Sneha S K and Sriparna Roy in Bengaluru;
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong growth prospects and low valuation.
IL2-CD25 by Bristol-Myers Squibb for Autoimmune Disorders: Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders.
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment Brightens
Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an injectable version of the pharmaceutical major’s cancer drug Opdivo. Opdivo is reportedly part of PD-1 inhibitors class of drugs,
Bristol-Myers gets FDA okay for injectable Opdivo
The FDA has reportedly approved an injectable formulation of Bristol-Myers Squibb's (NYSE:BMY) oncology drug Opdivo. Previously, the PD-1 inhibitor drug was only available through IV infusion. The injectable formulation,
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
Best Stocks for 10 Years. In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands ...
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slumped 0.55% to $57.68 Friday, on what proved to be an all-around poor trading ...
Business Insider16h
Halozyme Says FDA Approved Bristol Myers's Opdivo Qvantig With ENHANZE For Subcutaneous Use
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that the Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Opdivo Qvantig co-formulated with Halozyme's ENHANZE drug ...
FiercePharma7d
With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant Sotyktu
Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...
Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market
Shares of Bristol Myers Squibb Co. BMY inched 0.31% higher to $57.76 Tuesday, on what proved to be an all-around favorable ...
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...
Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 78%
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...